本报讯(记者张敏) 此次战略合作的升级，是创新药企与顶尖零售渠道的又一次强强联合。信达生物将持续提供包括信尔美 (玛仕度肽注射液)在内的治疗选择，而健之佳将凭借其全国性的零售网络、专业的药事服务与强大的品 牌影响力，助力这些创新产品更快速、更广泛地触达所需患者。 信达生物零售副总裁谭再强表示："信达生物高度重视零售渠道的建设与发展，我们将与健之佳一起探 索创新药物在零售端的发展模式，包括患者教育、药事服务、用药跟踪等全链条服务。" 健之佳副总裁柴治琦对双方未来的合作方向提出了具体建议。他表示，健之佳将充分发挥终端网络和专 业服务优势，与信达生物在产品推广、患者管理、健康服务等方面开展深入合作。 2026年1月5日，"信启新程，健赢未来"信达生物制药集团(以下简称"信达生物")与健之佳（605266）医 药连锁集团股份有限公司(以下简称"健之佳")战略合作对接会举行，双方正式签署2026年战略合作协 议。 信达生物创始人、董事会主席、首席执行官俞德超表示："在刚刚过去的2025年，我们与健之佳的合作 取得了令人瞩目的成绩。信尔美(玛仕度肽注射液)在健之佳渠道的良好落地与市场反馈，离不开健之佳 团队的高度重视与高 ...

Core Viewpoint - Xianweida Biotech has submitted its listing application to the Hong Kong Stock Exchange, focusing on innovative weight management therapies, with significant backing from notable investors [1][2]. Company Overview - Xianweida Biotech, founded in 2017, specializes in developing innovative therapies for obesity management and has raised approximately 2.2 billion yuan in funding [1][2]. - The company is nearing commercialization with its core product, Enoglutide Injection (XW003), which is expected to be the first cAMP biased GLP-1 receptor agonist globally [3][9]. Financial Performance - The company has reported cumulative losses exceeding 1.2 billion yuan, with projected revenues of 0 yuan for 2023 and 2024, and 91.07 million yuan for the first half of 2025 [2][11]. - R&D expenditures are significant, accounting for over 58% of total losses in recent years, indicating a strong focus on research activities [2]. Product Development - Enoglutide Injection (XW003) has shown promising clinical results, achieving a 15.1% weight reduction in overweight/obese patients, outperforming similar drugs [3][10]. - The product is expected to receive regulatory approval in China by mid-2026, with ongoing clinical trials to further validate its efficacy [3][10]. Market Position and Competition - The global weight management drug market is projected to grow from $112.8 billion in 2024 to $165.9 billion by 2029, with increasing demand for obesity-related treatments [6]. - The Chinese GLP-1 drug market has seen rapid growth, with a compound annual growth rate of 63% from 2019 to 2023, indicating strong market potential [6][8]. Strategic Partnerships - The company has established international collaborations, including licensing agreements for Enoglutide Injection in South Korea and other regions [4]. - Xianweida Biotech is building a diverse pipeline of GLP-1 and Amylin receptor agonist products, although most are still in early clinical stages [4]. Challenges Ahead - Despite its promising product pipeline, the company faces challenges in scaling production, market access, and sales channel development, which may impact future profitability [1][11]. - The competitive landscape for GLP-1 drugs is intensifying, with numerous companies entering the market, necessitating effective commercialization strategies [8][11].

Core Viewpoint - Xinda Biologics (01801) reported strong financial results for the six months ending June 30, 2025, with significant revenue growth and a return to profitability, driven by robust performance in its oncology product line and expansion of its product portfolio [1][2]. Financial Performance - The company achieved revenue of RMB 5.953 billion, a year-on-year increase of 50.6% [1] - Net profit reached RMB 834 million, marking a return to profitability compared to the previous period [1] - Basic earnings per share were RMB 0.51 [1] - Non-IFRS profit increased to RMB 1.213 billion, reflecting ongoing improvements in operational efficiency [1] Product Performance - Product revenue amounted to RMB 5.234 billion, representing a year-on-year growth of 37.3% [1] - The oncology product portfolio maintained a leading advantage, with strong performance from major products and continuous contributions from new product revenues [1] - The company successfully commercialized five new drugs during the reporting period, expanding its product portfolio to 16 products [2]

Core Viewpoint - The company, Innovent Biologics, reported significant financial growth for the six months ending June 30, 2025, with a 50.6% increase in revenue and a return to profitability, driven by strong performance in its oncology product line and expansion of its product offerings [1][2]. Financial Performance - Revenue from customer contracts reached RMB 5.953 billion, a year-on-year increase of 50.6% [1] - The company achieved a profit of RMB 834 million, marking a turnaround from previous losses [1] - Basic earnings per share were reported at RMB 0.51 [1] - Non-IFRS profit rose to RMB 1.213 billion, indicating improved operational efficiency [1] Product Performance - Product revenue totaled RMB 5.234 billion, reflecting a year-on-year growth of 37.3% [1] - The oncology product portfolio maintained a leading advantage, with strong performance from major products and continuous contributions from new product revenues [1] - The product portfolio has expanded to 16 products, with five new drugs successfully commercialized during the reporting period [2]

Core Insights - The company reported a revenue of RMB 5.953 billion for the six months ending June 30, 2025, representing a year-on-year increase of 50.6% [1] - The net profit reached RMB 834 million, marking a turnaround from a loss, with basic earnings per share at RMB 0.51 [1] - Revenue growth was primarily driven by strong performance in oncology products, expansion of the product line, and increased licensing income [1] Financial Performance - Product revenue amounted to RMB 5.234 billion, reflecting a year-on-year growth of 37.3% [1] - The significant improvement in IFRS profit to RMB 834 million and Non-IFRS profit rising to RMB 1.213 billion indicates ongoing operational efficiency enhancements [1] - The company achieved substantial improvements in net profit and EBITDA, benefiting from robust revenue growth and continuous optimization of operational efficiency [1] Product Development - The product portfolio has expanded to 16 products, with five new drugs successfully commercialized during the reporting period, including key oncology products [2] - The company demonstrated exceptional execution under a clear "dual-driven" and "global innovation" strategy, achieving strong revenue growth and significant profit enhancement [2] - Positive proof of concept data from the next-generation pipeline supports sustainable growth and global innovation, marking a strategic acceleration from leading in oncology to successful commercialization of the comprehensive product line [2]

Core Viewpoint - The company, Innovent Biologics, reported significant financial improvements for the six months ending June 30, 2025, with a revenue of RMB 5.953 billion, a year-on-year increase of 50.6%, and a profit of RMB 834 million, marking a turnaround from losses [1][2] Financial Performance - Revenue from customer contracts reached RMB 5.953 billion, reflecting a 50.6% increase year-on-year [1] - Net profit improved to RMB 834 million, with basic earnings per share at RMB 0.51 [1] - Non-IFRS profit rose to RMB 1.213 billion, indicating ongoing operational efficiency improvements [1] Product Development and Market Strategy - The product portfolio has expanded to 16 products, with five new drugs successfully commercialized during the reporting period [2] - Key new products include tumor drugs such as Daberan (Dabrafenib), Aoyixin (Leratinib), and Jiepali (Pimavanserin), along with other products in the comprehensive line [2] - The company’s strategy focuses on a "dual-driven" and "global innovation" approach, leading to strong revenue growth and significant profit improvements [2] Operational Efficiency - The company achieved substantial improvements in net profit and EBITDA, primarily driven by strong revenue growth and continuous optimization of operational efficiency [1]